Quirón­salud and UCAM in­ves­ti­gate treat­ments to fight can­cer

Per­son­al­ized vac­cines, the study of genes, and a mul­ti­dis­ci­plinary fo­cus im­prove re­sults and in­crease sur­vival rates, as an al­ter­na­tive to con­ven­tional meth­ods

Costa Blanca News (South Edition) - - Health -

Ad­ver­tis­ing fea­ture Hospi­tal Quirón­salud Tor­re­vieja has opened a clean room, de­signed to meet the in­ter­na­tional stan­dards for qual­ity GMP (Good Man­u­fac­tur­ing Prac­tices), and in­tended for the prepa­ra­tion of medicine for ad­vanced ther­a­pies, such as tu­mour cell vac­cines.

The med­i­cal team from the On­col­ogy plat­form at Hospi­tal Quirón­salud Tor­re­vieja, led by Doc­tor An­to­nio Bru­garo­las, is part of the Chair of mul­ti­dis­ci­plinary On­col­ogy at the UCAM (Catholic Univer­sity of Mur­cia).

The team have started the man­u­fac­tur­ing of den­dritic cells made with the pa­tient’s own blood, which has had pos­i­tive re­sults for treat­ing metastatic prostate can­cer. “As well as work­ing on this type of can­cer, the fu­ture plans for the clean room in­clude ob­tain­ing vac­cines to treat pa­tients with skin and breast can­cer”, ex­plains Doc­tor Juan José Mata, spe­cial­ist in im­munol­ogy at Hospi­tal Quirón­salud Tor­re­vieja. A new tech­nol­ogy based on

the study of genes Fol­low­ing in the line of work of per­son­al­ized treat­ment to fight can­cer, Hospi­tal Quirón­salud Tor­re­vieja is ini­ti­at­ing a Next Gen­er­a­tion Se­quencer to find out how each tu­mour be­haves by study­ing the DNA and ARN in pa­tients that are re­sis­tant to con­ven­tional chemo­ther­apy. “It means we can look for ge­netic al­ter­ations of DNA in all tu­mours.

Up un­til now 20% of pa­tients had DNA mu­ta­tions which were treat­able, and hope­fully now that per­cent­age will in­crease” high­lights Doc­tor Bru­garo­las. In ad­di­tion, he ex­plains that not only do they aim to de­tect the mu­ta­tions that are treat­able to ad­min­is­ter the cor­rect treat­ment, but also they want to know how the cells re­act to the mu­ta­tions, that way they can vi­su­al­ize how the cell adapts and pre­dict the chemo­ther­apy that is best for each tu­mour.

This new tech­nol­ogy im­plies that the pa­tient only needs one biopsy and they get the re­sults back in just two weeks. In ad­di­tion, it gives the pa­tient a choice between dif­fer­ent treat­ments de­pend­ing on the costs, the side ef­fects, the method of in­take, and the pa­tient’s pref­er­ences mean­ing that the method is per­son­al­ized.

On av­er­age 600 genes are stud­ied in just one test which is more re­li­able than con­ven­tional chemo­ther­apy, and can pre­dict which are the best drugs to fight the can­cer. Al­though the treat­ment still needs to be per­fected, Doc­tor Bru­garo­las con­cludes “By analysing a pa­tient’s ARN, their re­sponse to chemo­ther­apy treat­ment can be pre­dicted with 70% ac­cu­racy”. A high res­o­lu­tion mul­ti­dis­ci­plinary con­cept The on­col­ogy plat­form at Hospi­tal Quirón­salud Tor­re­vieja is com­posed of a mul­ti­dis­ci­plinary team of more than 30 top level spe­cial­ists, and state of the art tech­nol­ogy such as PET-CT, in­tra­op­er­a­tive ra­dio­ther­apy (mo­be­trón), per­son­al­ized phar­ma­cother­apy, ge­netic coun­selling, or the clean room; which have made it an in­ter­na­tional cen­tre of ref­er­ence for di­ag­no­sis and can­cer treat­ment, vis­ited by pa­tients from Spain and Europe.

The Chair of mul­ti­dis­ci­plinary On­col­ogy at the UCAM and Quirón­salud Tor­re­vieja have worked to­gether for sev­eral years, to de­velop re­search which later has been put to prac­tice at the Hospi­tal, such as the HIPEC tech­nique which con­sists in ap­ply­ing chemo­ther­apy with hy­per­ther­mia in­side the ab­domen dur­ing surgery. This tech­nique which has been ap­plied at the On­col­ogy plat­form at Hospi­tal Quirón­salud Tor­re­vieja for over 15 years, has re­cently been in­tro­duced in most ma­jor hos­pi­tals in Spain. Af­ter many years of re­search, it has proven to be 30% ef­fec­tive in pa­tients with peri­toneal car­ci­no­mato­sis, and is ac­cepted in the sci­en­tific com­mu­nity as be­ing the best al­ter­na­tive for metastatic peri­toneal ovar­ian or colon can­cer.

Newspapers in English

Newspapers from Spain

© PressReader. All rights reserved.